NCT04943627 2022-10-05Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)Agenus Inc.Phase 3 Withdrawn
NCT03744247 2019-05-02Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCSun Yat-sen UniversityPhase 3 Withdrawn
NCT03791918 2019-05-02Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaSun Yat-sen UniversityPhase 3 Withdrawn